Actavis' clients launch generic Atorvastatin in Spain

Actavis Group, the international generic pharmaceuticals company, today announced that its third-party sales division, Medis, has delivered 30 million tablets of Atorvastatin to its clients in Spain. This is the first generic version of the blockbuster molecule to reach the Spanish market.

The product, Atorvastatin Magnesium, is launched by four of Spain's largest generic pharmaceutical companies. Distribution of the product to Spanish pharmacies has already commenced.

Atorvastatin efficiently regulates the blood cholesterol levels and is one of the most effective drugs used in the therapy of primary hypercholesterolemia. Atorvastatin Magnesium is produced by Actavis in 10mg, 20mg and 40mg tablets. Pfizer, the originator, markets its product in Spain under the brand names of Cardyl® and Zarator®. Atorvastatin's US brand name is Lipitor®.

Atorvastatin tablets are subject to widely varying patent situations around the world, which is why Medis has invested significantly in different forms of the molecule. In Spain, the patent landscape is different to other Western European markets, and the originator product, containing Atorvastatin Calcium, is patented until 2010.

Medis is currently promoting three different dossiers for Atorvastatin and has been supplying a product suitable for Central Eastern Europe for close to two years. Medis' alternative generic, Atorvastatin Magnesium, can be launched in Spain now, as it has been approved by the Spanish authorities. Medis has worked closely with its clients on the preparations for the launch.

Actavis has already launched Atorvastatin Calcium under its own brand name in 15 countries in Europe and Asia where there was no patent. Atorvastatin Magnesium will be launched in Spain under Actavis' own brand name shortly.

Annual sales of Cardyl® and Zarator® in Spain are approximately EUR 396 million (2008, IMS Health). Atorvastatin is currently the top selling drug in Spain, and indeed the world.